{
  "docId": "019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "docSlug": "5e172cf8223e03a5f49c2e34f7f0a14c",
  "documentTitle": "Valneva | IPO Presentation Deck | 41 slides",
  "authorId": "valneva",
  "authorName": "Valneva",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4117647,
  "pageNumber": 32,
  "pageCount": 41,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-f16a-77fb-9c90-c741a7f6a0f0/32",
  "deckHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "deckJsonHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0.json",
  "deckAnchorHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.06,
        "y": 0.69
      },
      "kind": "list",
      "text": "Additional studies planned",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "399caf7c-c354-4348-9aac-be04fe659695",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.1,
        "y": 0.39
      },
      "kind": "list",
      "text": "Immunological comparison against a licensed vaccine to reasonably predict efficacy (superiority of VLA2001 in a two-dose immunization schedule four weeks apart - GMTs of neutralising antibodies, at two weeks after the second vaccination)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5714da97-5cb9-49a2-8639-d42460a0b0bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "list",
      "text": "Booster studies (including reduced booster dose)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b9d7fb8-84dc-4714-ba7a-fa04d0290394",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.1,
        "y": 0.59
      },
      "kind": "list",
      "text": "Protocol agreed with MHRA; discussion with other regulatory bodies ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "746025ea-da68-4252-b697-98c7629631f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.06,
        "y": 0.29
      },
      "kind": "list",
      "text": "Pivotal Phase 3 is a randomized, observer-blind, controlled, comparative immunogenicity trial in ~ 4,000 adults",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a51f536f-8067-4813-ad92-8f1caa56b7cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.1,
        "y": 0.53
      },
      "kind": "list",
      "text": "Study conducted in UK supported by DHSC/NIHR, including funding",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c457b17f-d990-493d-a2d4-5f92e5eab5fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.06,
        "y": 0.1
      },
      "kind": "title",
      "text": "Pivotal Phase 3 Trial Initiated",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8896bc21-f8b8-4781-bef0-9c1d9f26d183",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.06,
        "y": 0.05
      },
      "kind": "title",
      "text": "VLA2001: Development Outlook",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "676696d3-7d2b-4c36-b679-22eadd21938b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}